Navigation Links
Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
Date:5/13/2010

SAN DIEGO, May 13 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

Human anti-chimeric antibody (HACA) levels have been associated with decreased duration of response and increased side effects in infliximab-treated patients (1). Current methods for detecting HACA are limited by the presence of infliximab and therefore require a minimum of 8 weeks following therapy for accurate measurement. To overcome these limitations, Prometheus has developed a proprietary highly sensitive method to measure HACA and infliximab levels in patient serum in real time. The Company believes this method can also be applied to detect other biologic drugs and their antibodies.

"Early and accurate detection of antibody levels during the course of biologic therapy may enhance our ability to assess reasons for loss of response," said David Rubin, M.D., Associate Professor of Medicine, Co-Director, University of Chicago Inflammatory Bowel Disease Center. "In addition, we anticipate that therapeutic monitoring of biologic therapy may become routine in our approach to individualizing therapies to maximize effectiveness and minimize adverse events."

Data from a preliminary study of this novel method for early detection of HACA during infliximab treatment were recently presented by Prometheus scientists at Digestive Disease Week (DDW), the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. The presentation, entitled "Measurement of Human Anti-Chimeric Antibodies (HACA) and Infliximab Levels in Patient Serum Using a Novel Homogeneous Assay," was awarded Poster of Distinction by the DDW sponsoring societies.

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.

(1)Afif W et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133-9.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
2. Prometheus Launches ProOnc Dx Cancer Diagnostics
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
5. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
6. DUSA Pharmaceuticals Announces Slate of Nominees for Election to the Board of Directors
7. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
8. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
9. Cogdell Spencer Announces Commencement of Common Stock Offering
10. Mylan Announces Upsizing and Pricing of Senior Notes
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Jeffrey Zucker , vice ... will present at this year,s Summit for Clinical Operations Executives ... Miami, FL. Zucker will discuss how ... execution, supporting SCOPE,s "Improving Site Study Activation and Performance" portion ... Feb. 25 at 11:05 a.m. --> ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus Pharmacy ... providing high-quality specialty pharmacy care for those suffering ... it has achieved full Specialty Pharmacy Accreditation from ... dedicated to promoting health care quality through accreditation, ... --> The URAC accreditation process demonstrates ...
(Date:2/11/2016)... 11, 2016 SI-BONE, Inc., a medical ... iFuse Implant System, a minimally invasive surgical (MIS) ... the sacroiliac (SI) joint, announced the publication of ... MIS SI joint fusion for patients suffering from ... or SI joint disruption.  In the first article, ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... "What holds ... author Ray Clarke poses a question as a challenge for his readers to ... "Being in the Being" (published by Partridge Singapore), Clarke explores the subject with ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... practice Village Family Practice , will be presenting at the 2016 HIMSS ... Las Vegas, Nev. , During his session, “ Coding for Care: Using ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the ... of DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel ... list. The panel’s goal is to recognize and promote technology entrepreneurship. , The ...
(Date:2/11/2016)... Washington, D.C. (PRWEB) , ... February 11, 2016 ... ... will be exhibiting at the American Academy of Dermatology Annual Meeting at ... Hidrex USA's goal is to raise awareness for both the condition of hyperhidrosis ...
Breaking Medicine News(10 mins):